JP2004519431A - 腫瘍溶解性ウイルス - Google Patents

腫瘍溶解性ウイルス Download PDF

Info

Publication number
JP2004519431A
JP2004519431A JP2002545626A JP2002545626A JP2004519431A JP 2004519431 A JP2004519431 A JP 2004519431A JP 2002545626 A JP2002545626 A JP 2002545626A JP 2002545626 A JP2002545626 A JP 2002545626A JP 2004519431 A JP2004519431 A JP 2004519431A
Authority
JP
Japan
Prior art keywords
virus
reovirus
gene
protein
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002545626A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004519431A5 (https=
Inventor
アール ガーネット ブラウン，
ジーン ルタムヨ ムビサ，
ジョン キャメロン ベル，
デイビッド フランシス ストッジュル，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Ottawa
Original Assignee
University of Ottawa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Ottawa filed Critical University of Ottawa
Publication of JP2004519431A publication Critical patent/JP2004519431A/ja
Publication of JP2004519431A5 publication Critical patent/JP2004519431A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2002545626A 2000-12-01 2001-11-30 腫瘍溶解性ウイルス Pending JP2004519431A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25013100P 2000-12-01 2000-12-01
US32701601P 2001-10-05 2001-10-05
PCT/CA2001/001703 WO2002043647A2 (en) 2000-12-01 2001-11-30 Oncolytic virus

Publications (2)

Publication Number Publication Date
JP2004519431A true JP2004519431A (ja) 2004-07-02
JP2004519431A5 JP2004519431A5 (https=) 2005-12-22

Family

ID=26940619

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002545626A Pending JP2004519431A (ja) 2000-12-01 2001-11-30 腫瘍溶解性ウイルス

Country Status (5)

Country Link
EP (1) EP1339736A2 (https=)
JP (1) JP2004519431A (https=)
AU (2) AU2002220416A1 (https=)
CA (1) CA2430495A1 (https=)
WO (2) WO2002043647A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010520758A (ja) * 2007-03-12 2010-06-17 オンコリティクス バイオテク，インコーポレーテッド 改変配列を有するレオウイルス

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
WO2005111200A1 (en) * 2004-05-17 2005-11-24 Universite De Montreal Novel strains of reoviruses and methods of uses thereof
WO2007099401A2 (en) 2005-08-01 2007-09-07 University Technologies International, Inc. Oncolytic attenuated reoviruses for treatment of proliferative disorders
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
WO2019237063A1 (en) * 2018-06-07 2019-12-12 Emory University Modified reoviruses, particles, and uses in treating proliferative disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
CA2323067A1 (en) * 1998-03-12 1999-09-16 The Trustees Of The University Of Pennsylvania Producer cells for replication selective viruses in the treatment of malignancy

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010520758A (ja) * 2007-03-12 2010-06-17 オンコリティクス バイオテク，インコーポレーテッド 改変配列を有するレオウイルス
US8691241B2 (en) 2007-03-12 2014-04-08 Oncolytics Biotech Inc. Reoviruses having modified sequences
US10039827B2 (en) 2007-03-12 2018-08-07 Oncolytics Biotech Inc. Reoviruses having modified sequences
US10596260B2 (en) 2007-03-12 2020-03-24 Oncolytics Biotech Inc. Reoviruses having modified sequences
US11246930B2 (en) 2007-03-12 2022-02-15 Oncolytics Biotech Inc. Reoviruses having modified sequences

Also Published As

Publication number Publication date
AU2002220416A1 (en) 2002-06-11
WO2002050304A2 (en) 2002-06-27
AU2002243257A1 (en) 2002-07-01
EP1339736A2 (en) 2003-09-03
WO2002043647A3 (en) 2003-01-03
WO2002043647A2 (en) 2002-06-06
WO2002050304A3 (en) 2002-11-28
CA2430495A1 (en) 2002-06-06

Similar Documents

Publication Publication Date Title
JP5060694B2 (ja) 腫瘍崩壊性ウイルス
Hundley et al. Genome rearrangements of bovine rotavirus after serial passage at high multiplicity of infection
CA2305269C (en) Treatment of neoplasms with viruses
Gao et al. Newcastle disease virus RNA-induced IL-1β expression via the NLRP3/caspase-1 inflammasome
US20070036758A1 (en) Mutants of vaccinia virus as oncolytic agents
Estes et al. Heterogeneity in the structural glycoprotein (VP7) of simian rotavirus SA11
Mei et al. First evidence that an emerging mammalian alphacoronavirus is able to infect an avian species
Li et al. Emerging lethal infectious bronchitis coronavirus variants with multiorgan tropism
Li et al. Characterization and pathogenicity of a novel mammalian orthoreovirus from wild short-nosed fruit bats
Liu et al. Enhanced pathogenicity and transmissibility of H9N2 avian influenza virus in mammals by hemagglutinin mutations combined with PB2-627K
Wakamatsu et al. The effect on pathogenesis of Newcastle disease virus LaSota strain from a mutation of the fusion cleavage site to a virulent sequence
US20040115170A1 (en) Oncolytic virus
JP2004519431A (ja) 腫瘍溶解性ウイルス
Zhang et al. Phylogenetic Analysis of ALV‐J Associated with Immune Responses in Yellow Chicken Flocks in South China
Ricordel et al. Oncolytic properties of non-vaccinia poxviruses
CN116814564A (zh) 重组表达凋亡素蛋白的溶瘤流感病毒的制备方法及应用
JP3756219B2 (ja) レオウイルス株２１７７及び該株を含むワクチン
Wang et al. Attenuate Newcastle disease virus by codon modification of the glycoproteins and phosphoprotein genes
US12295977B2 (en) Oncolytic reovirus
平山紀夫 et al. Comparison of biological and molecular properties among canine distemper virus strains.
US11332756B2 (en) RNA virus vectors carrying DAI and RIPK3
Feng et al. MGF505‐7R and I267L Deletions Attenuate African Swine Fever Virus and Confer Protection Against the Virulent Pandemic Virus in Pigs
Lela et al. Mammalian orthoreovirus: Pathogenicity, zoonotic potential, and therapeutic promise
Eledge Mechanisms and Consequences of Type-1 Interferon Activation by Mammalian Orthoreovirus
Mann et al. Type 3 reovirus neuroinvasion after intramuscular inoculation: viral genetic determinants of lethality and spinal cord infection

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20050331

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20050624

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20050707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050928

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20060406